Hashimoto’s Thyroiditis – the Need for a Specific Therapy

Johannes Ott 1*
Department of Gynaecologic Endocrinology and Reproductive Medicine, Medical University of Vienna, Austria

Hashimoto’s thyroiditis (HT) is one of the most common autoimmune disorders and is the most prevalent cause of subclinical or overt hypothyroidism in areas with sufficient iodine intake [1]. Over the last three decades, its incidence has increased substantially, regardless whether it was defined by laboratory, clinical and ultrasonographic features [2] or histological characteristics [3]. Moreover, various characteristics of HT have changed over the decades. Affected patients had become younger and the incidence of clinically diagnosed HT in males had increased [2].

Apart from its substantial impact on thyroid function, HT also influences general health independent from hypo- or hyperthyroidism [4]. It is associated with decreased quality of life levels [5] as well as a wide range of organ-specific and non-organ-specific autoimmune disorders, as well as other diseases, including neuropsychological/psychiatric deficits, disorders of the gut, fibromyalgia, and reproductive health issues, among many others [4].

Thus, one of the main questions is whether HT patients who suffer from impairment in quality of life and HT-related symptoms can find medical help. Evidence suggests that both levothyroxine replacement and selenium supplementation are associated with a decrease in concentrations of thyroid peroxidase antibodies [6,7]. However, no improvements in thyroid function have been observed with these approaches. Thyroidectomy, on the other hand, will only lead to a relief of mechanical symptoms including a feeling of compression, voice problems and tightness in the neck [8,9]. Keeping in mind that the association between HT and other autoimmune diseases likely derives from a polyclonal autoimmune response against organ-specific autoantigens [10], thyroidectomy will not lead to improvements in a majority of associated conditions and, thus, will only have minor impact on overall quality of life [4].

Notably in HT patients, low-level laser therapy of the thymus, thyroid, and supravacular fossa induces systemic immunomodulation [11]. A recent randomized, placebo-controlled trial on the efficacy of low-level laser therapy in patients with HT-induced hypothyroidism demonstrated that thyroid function was improved and thyroid peroxidase antibody levels were reduced [12]. This effect was also evident at the last follow-up examination nine months after treatment.

HT is considered a multifactorial disease. Recently, Effraimidis et al. [13] proposed a model for the natural history of autoimmune thyroid disease suggesting that a particular genetic background allows development of autoantibodies against thyroid peroxidase. Then, environmental exposure plays a significant role whether the patient will become hyper- or hypothyroid; for example, a high iodine intake and refraining from smoking will favor development toward hypothyroidism [13]. Together with possible influences of radiation [14], the sex hormones [15], and fetal microchimerism [16] the development is based on a variety of factors. Thus, it seems unlikely that primary prevention will be possible. Moreover, HT is a gender-specific disease with a current female-to-male ratio of about 7:1 [17] and, in addition with the above-mentioned associated conditions, it influences female and reproductive health substantially [4].

These considerations and the rising incidence of HT suggest that a specific therapy is needed. Unfortunately, with selenium and levothyroxine supplementation, thyroidectomy and laser therapy only a few therapeutic approaches have been developed and investigated. Hopefully, clinicians and researchers will realize that HT can substantially and directly influence health and health-related quality of life in many patients and will become eager to develop new specific treatment options.

References

*Corresponding author: Johannes Ott, Department of Gynaecologic Endocrinology and Reproductive Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria, E-mail: johannes.ott@meduniwien.ac.at

Received August 16, 2012; Accepted August 18, 2012; Published August 20, 2012

Citation: Ott J (2012) Hashimoto’s Thyroiditis – the Need for a Specific Therapy. Thyroid Disorders Ther 1: e105. doi:10.4172/2167-7948.1000e105

Copyright: © 2012 Ott J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


